Asthma & COPD 2018

11/04/2018 - 12/04/2018

Asthma & COPD 2018

Improving health outcomes and revolutionising clinical trials with real world studies

11th – 12th April 2018

Copthorne Tara Hotel, London, UK



SMi is pleased to present the return of the 14th annual Asthma & COPD Conference taking place on 11th – 12th April 2018, London, UK.

Recent advances in injectable biologics and smart medical devices as led to an increase in novel approaches to treating severe asthma and COPD as well as the regulations to take into consideration. As technology soars, the need for guideline updates from regulators has increased and continues to be modified.

With asthma and chronic obstructive pulmonary disorder (COPD) affecting about 500 million people worldwide, opportunities in drug development are vast and reducing serious attacks by improving adherence could save $19 billion a year in U.S. healthcare costs.

Join us as we discuss current clinical trials and the innovative digital technology being used to improve clinical adherence. Leading industry experts will be looking at the use of ‘real world data’ human factors in the design of medical devices and triple combination treatments on the market. We will also be looking at asthma and COPD Phenotyping and biomarker application and differences between in the EU and US for the approval of biologics. We will be exploring the complexities of dry powder formulation and helping you determine clinical efficacy and endpoints.
Topics of Discussion for 2018

  • Early detection and prevention of COPD and Asthma
  • The use of triple combination therapies
  • Health economics and market access for innovative treatments
  • Regulatory updates in bioequivalence and drug-device combinations
  • Enhancing dry powder formulation
  • Asthma and COPD Phenotyping and biomarker application for personalised medicines



  • Wisia Wedzicha, Professor of Respiratory Medicine and Head of Respiratory Clinical Science, Imperial College London


  • Quan Yang, Senior Pharmaceutical Assessor, MHRA
  • Maria Gerhardsson de Verdier, Director of Epidemiology, AstraZeneca
  • René van der Merwe, Senior Director Respiratory & Inflammation, MedImmune
  • Alison Moore, Clinical Development Director, GSK
  • Peter Barnes, Head of Respiratory Medicine, Imperial College London
  • Jonathan Phillips, Principal Scientist, Inflammation, Amgen
  • Christopher Stevenson, Venture Leader – COPD, Disease Interception Accelerator, Janssen
  • Georg Brauers, Senior Manager Regulatory Affairs, Boehringer Ingelheim


For further information about Asthma & COPD 2018, please visit